Kiniksa files Form 144 for 219,591 shares

Kiniksa Pharmaceuticals submitted a Form 144 reporting 219,591 Class A ordinary shares related to an employee stock option exercise on 04/06/2026.

Accepted by SEC EDGAR 04/06/2026 - 04:54 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals submitted a Form 144 reporting 219,591 Class A ordinary shares related to an employee stock option exercise on 04/06/2026. The filing lists $10,979,550.00 in an adjacent field and a reference number of 45,900,637, with broker handling by Charles Schwab & Co.

Key Figures

Shares reported: 219,591 shares Adjacent dollar field: $10,979,550.00 Row reference number: 45,900,637 +2 more

5 metrics

Shares reported 219,591 shares Class A Ordinary Share reported on <date>04/06/2026

Adjacent dollar field $10,979,550.00 Listed in the same row as the 219,591-share entry

Row reference number 45,900,637 Numeric value appearing in the sale row on <date>04/06/2026

Filing date 04/06/2026 Date tied to the securities sale/exercise entry

Broker Charles Schwab &amp; Co., Inc. Broker named for the transaction handling

Key Terms

Employee Stock Option Exercise, Broker Payment for Cashless Exercise, Form 144

3 terms

Employee Stock Option Exercise financial

"Employee Stock Option Exercise - See Remarks"

Broker Payment for Cashless Exercise financial

"Broker Payment for Cashless Exercise"

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 report on 04/06/2026?

It reports the proposed sale of 219,591 Class A ordinary shares. The filing ties the shares to an employee stock option exercise and lists brokerage handling by Charles Schwab on 04/06/2026.

Was the 219,591-share transaction a cashless exercise for KNSA?

Yes, the filing describes the transaction as a Broker Payment for Cashless Exercise. It indicates shares were allocated or sold to satisfy option exercise obligations via the broker.

Which broker is named in the KNSA Form 144 filing?

The filing names Charles Schwab & Co., Inc. as the broker. The broker address line appears alongside the share and dollar figures on the Form 144 excerpt.

Does the Form 144 excerpt show an aggregate dollar amount?

An adjacent field shows $10,979,550.00 next to the share count. The excerpt presents that number in the same row as the 219,591 shares and date 04/06/2026.

Is there an outstanding shares figure noted in the excerpt for KNSA?

The excerpt includes the number 45,900,637 in the same row as the sale entry. The filing text does not explicitly label it beyond its placement on that line.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001532218
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Patel Sanj K
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	219591	10979550.00	45900637	04/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	04/06/2026	Employee Stock Option Exercise - See Remarks	Kiniksa Pharmaceuticals, Ltd.			219591	04/06/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The options on this filing may be sold over various dates.
Date of Notice	04/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sanj K Patel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)